MedTrace Logo

Gemcitabine Hydrochloride and Cisplatin Before Surgery in Treating Patients With Muscle Invasive Bladder Cancer

NCT01611662 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2019-07-29

Study results available
· View outcomes & findings →

Summary

The purpose of this research study is to find out what effects, good and/or bad, dose-dense (every 14 days) chemotherapy with gemcitabine (gemcitabine hydrochloride) and cisplatin given before surgery have on patients and their muscle invasive bladder cancer.

Conditions

  • Distal Urethral Cancer
  • Proximal Urethral Cancer
  • Squamous Cell Carcinoma of the Bladder
  • Stage II Bladder Cancer
  • Stage III Bladder Cancer
  • Urethral Cancer Associated With Invasive Bladder Cancer

Interventions

DRUG

gemcitabine hydrochloride

Given IV

DRUG

cisplatin

Given IV

PROCEDURE

therapeutic conventional surgery

Undergo radical cystectomy

OTHER

laboratory biomarker analysis

Correlative studies

Sponsors & Collaborators

  • Fox Chase Cancer Center

    lead OTHER

Principal Investigators

  • Elizabeth Plimack · Fox Chase Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-05-29
Primary Completion
2013-07-12
Completion
2019-01-22

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01611662 on ClinicalTrials.gov